A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect anatomical or functional outcomes after epiretinal membrane surgery.
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration. InflammX Therapeutics, Inc. has entered into an option agreement granting ...
A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need ...
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides ...
Australian researchers have identified an association between nocturnal hypoxia and neovascular age-related degeneration (nAMD). 1 Acting on this realization could prevent nAMD in some patients, ...
4D Molecular Therapeutics (4DMT) released positive topline interim data from Part 1 of the SPECTRA clinical trial. This trial is designed to evaluate 4D-150 in diabetic macular edema (DME) and ...
Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their ...